ENSARTINIB

ENSARTINIB was reported 45 times

ENSARTINIB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 INFLAMMATORY MYOFIBROBLASTIC TUMOUR 1 0.0077
1 LUNG ADENOCARCINOMA STAGE IV 1 0.0026
2 PELVIC FLUID COLLECTION 1 0.0014
3 TUMOUR PSEUDOPROGRESSION 1 0.0009
4 MYOCARDIAL INJURY 1 0.0009
5 SMALL CELL LUNG CANCER 1 0.0007
6 MYOCARDIAL NECROSIS MARKER INCREASED 1 0.0006
7 ORGAN FAILURE 1 0.0002
8 ANAPHYLACTOID REACTION 1 0.0002
9 EAR DISORDER 1 0.0002
10 INTRACRANIAL PRESSURE INCREASED 1 0.0002
11 METASTASES TO LYMPH NODES 1 0.0001
12 METASTASIS 1 0.0001
13 TROPONIN INCREASED 1 0.0001
14 HAEMOLYTIC ANAEMIA 1 0.0001
15 SINUS BRADYCARDIA 1 0.0001
16 BRAIN INJURY 1 0.0001
17 MOUTH ULCERATION 2 0.0001
18 SKIN INFECTION 1 0.0001
19 MYOCARDITIS 1 0.0001
20 SPLENOMEGALY 1 0.0001
21 HYPERLIPIDAEMIA 1 0.0001
22 ADRENAL INSUFFICIENCY 1 0.0001
23 DRUG RESISTANCE 2 0.0001
24 METASTASES TO CENTRAL NERVOUS SYSTEM 1 0.0001
25 OEDEMA 4 0.0001
26 CENTRAL NERVOUS SYSTEM LESION 1 0.0001
27 SKIN HAEMORRHAGE 1 0.0001
28 PNEUMOTHORAX 1 0.0001
29 FACE OEDEMA 1 0.0001
30 RASH PRURITIC 3 0.0001
31 SKIN FISSURES 1 0.0001
32 TASTE DISORDER 1 0.0000
33 PERICARDIAL EFFUSION 1 0.0000
34 NEURALGIA 1 0.0000
35 AGEUSIA 1 0.0000
36 MUCOSAL INFLAMMATION 1 0.0000
37 ASPARTATE AMINOTRANSFERASE INCREASED 2 0.0000
38 INTENTIONAL DOSE OMISSION 1 0.0000
39 LIVER FUNCTION TEST ABNORMAL 1 0.0000
40 DISEASE PROGRESSION 4 0.0000
41 BLOOD POTASSIUM DECREASED 1 0.0000
42 PLEURAL EFFUSION 2 0.0000
43 ALANINE AMINOTRANSFERASE INCREASED 2 0.0000
44 ADVERSE EVENT 3 0.0000
45 EMOTIONAL DISORDER 1 0.0000
46 DRUG-INDUCED LIVER INJURY 1 0.0000
47 NEOPLASM PROGRESSION 1 0.0000
48 CONSTIPATION 6 0.0000
49 HEPATIC FUNCTION ABNORMAL 1 0.0000
50 INTESTINAL OBSTRUCTION 1 0.0000
51 SWELLING 2 0.0000
52 ARRHYTHMIA 1 0.0000
53 RASH 9 0.0000
54 ATRIAL FIBRILLATION 2 0.0000
55 PRURITUS 7 0.0000
56 PRODUCT USE ISSUE 3 0.0000
57 BLOOD CREATININE INCREASED 1 0.0000
58 INFECTION 2 0.0000
59 CONFUSIONAL STATE 2 0.0000
60 SKIN EXFOLIATION 1 0.0000
61 ADVERSE DRUG REACTION 1 0.0000
62 DRUG INTOLERANCE 1 0.0000
63 SYNCOPE 1 0.0000
64 CHEST DISCOMFORT 1 0.0000
65 MALIGNANT NEOPLASM PROGRESSION 1 0.0000
66 HAEMORRHAGE 1 0.0000
67 PLATELET COUNT DECREASED 1 0.0000
68 DECREASED APPETITE 2 0.0000
69 DRY SKIN 1 0.0000
70 VISION BLURRED 1 0.0000
71 HOSPITALISATION 1 0.0000
72 FATIGUE 5 0.0000
73 MYALGIA 1 0.0000
74 ALOPECIA 1 0.0000
75 HYPOTENSION 1 0.0000
76 ABDOMINAL PAIN UPPER 1 0.0000
77 DEATH 4 0.0000
78 OVERDOSE 1 0.0000
79 BACK PAIN 1 0.0000
80 PRODUCT USE IN UNAPPROVED INDICATION 1 0.0000
81 DRUG INEFFECTIVE 5 0.0000
82 INSOMNIA 1 0.0000
83 PRODUCT DOSE OMISSION ISSUE 1 0.0000
84 CONDITION AGGRAVATED 1 0.0000
85 DIARRHOEA 2 0.0000
86 PNEUMONIA 1 0.0000
87 PYREXIA 1 0.0000
88 VOMITING 1 0.0000
89 DIZZINESS 1 0.0000
90 NAUSEA 1 0.0000